Posts by: Patricia Inacio PhD

Patricia Inacio PhD

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

February 8, 2021February 8, 2021

Phase 3 Trial of Therapy for Inflammation, Insulin-sensitivity in Alzheimer’s to Open

News

NeurMedix has announced it will soon open a pivotal Phase 3 clinical trial of its lead investigational therapy, NE3107, for people with Alzheimer’s disease, following authorization by the U.S. Food and Drug ... Read more

January 25, 2021January 25, 2021

Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status

News

Cognito Therapeutic’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the ... Read more

December 21, 2020December 21, 2020

Fujirebio Seeks FDA’s Premarket Approval for Diagnostic Test

News

Fujirebio Diagnostics has submitted a premarket notification — also known as a 510(k) — to the U.S. Food and Drug Administration (FDA) for its Alzheimer’s diagnostic test, called Lumipulse ... Read more

December 16, 2020December 16, 2020

Biogen, Eisai Request Approval of Aducanumab for Alzheimer’s in Japan

News

Biogen and Eisai are seeking approval of aducanumab (BIIB037) for the treatment of Alzheimer’s disease in Japan, the companies have announced. If approved, aducanumab will become the first therapy with ... Read more

November 25, 2020November 25, 2020

AlzeCure’s Lead Therapy Candidate Entering Phase 1 Testing in Sweden

News

AlzeCure Pharma is preparing to launch a Phase 1 clinical trial in Sweden to evaluate the tolerability and safety of ACD856, one of its therapy candidates for Alzheimer’s disease, ... Read more

June 29, 2020June 29, 2020

Investigational Agitation Treatment AXS-05 Named FDA Breakthrough Therapy

News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to Axsome Therapeutics‘ AXS-05, an investigational oral therapy for the treatment of agitation in people with Alzheimer’s ... Read more

June 1, 2020June 1, 2020

FDA Approves Tauvid as First Tau Protein Tracer Tool for Alzheimer’s Diagnosis

News

The U.S. Food and Drug Administration (FDA) has approved Tauvid (flortaucipir F18) as an imaging radiotracer agent — a radioactive diagnostic tool — to efficiently detect clumps of tau protein ... Read more

April 3, 2020April 3, 2020

Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments

News

Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance ... Read more

March 23, 2020March 23, 2020

Moderate Drinking Linked to Lower Amyloid-Beta Levels, Study Says

News

Moderate lifetime alcohol intake in middle-aged and older people who don’t show signs of dementia is associated with lower deposits of amyloid-beta, the protein that forms toxic aggregates in ... Read more

February 24, 2020February 24, 2020

Phase 2 Trial into Potential Oral Alzheimer’s Treatment Safe to Continue, Independent Board Says

News

A Phase 2 clinical trial testing Annovis Bio‘s oral therapy ANV401 (also known as Posiphen) in people with early Alzheimer’s disease can continue without changes, according to a positive review ... Read more